Compare Novo Nordisk A/S (NVO) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Packaging Corporation of America — how do they compare? Novo Nordisk A/S trades at $44.76 (market cap $200.69B), while Packaging Corporation of America trades at $227.95 (market cap $20.67B). The key difference: Novo Nordisk A/S is far larger — about 9.7× Packaging Corporation of America's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | PKG | |
|---|---|---|
Market Cap | $200.69B | $20.67B |
Sector | Health | Technology |
52-Week High | $63.98 | $257.43 |
52-Week Low | $35.29 | $191.68 |
Enterprise Value | $215.49B | $24.48B |
Dividend Yield | 3.98% | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Packaging Corporation of America (PKG) trades at $231.99, down 2.22% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 30.13 above industry averages, while profitability metrics indicate solid ROE of 14.79% amid margin pressures. Recent news highlights dividend declarations and CEO participation in industry conferences, though cash flow trends show negative net flows driven by significant capital investments.
PKG presents a cautious outlook with analyst consensus leaning hold (57.69%) despite a $272.83 price target suggesting 17.6% upside. Investment appeal hinges on execution amid cost headwinds, while risks include margin compression and competitive pressures. The technical setup near support at $230 requires monitoring for potential breakdown or reversal signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
